BBNX
Health check
See the tests
- ✗Positive net income
- ✗Positive operating cash flow
- ✓Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Computed by Coteau from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Live chart
What they do
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
For information only · Important disclosures
Grades vs sector
No sector grades for BBNX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-2.16 vs trailing $-1.64. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score 14.9 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $100.3M | $-73.2M | $-56.2M |
| 2024 | $65.1M | $-54.8M | $-51.7M |
| 2023 | $12.0M | $-44.1M | $-32.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
In line = within 1% of the estimate.
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $32.0M | +37.8% |
| 2026-03-31 | $27.6M | – |
| 2025-12-31 | $32.1M | – |
| 2025-09-30 | $27.3M | – |
| 2025-06-30 | $23.2M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$13.4K
$7.0K
$147.9K
$58.3K
$619.6K
$12.0K
$680.7K
$113.3K
$322.4K
$127.6K
$83.6K
$80.7K
Stats refreshed 2026-10-21 18:23:14 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026